Drug Profile
Research programme: phosphatidylcholine-complexed therapeutics - PLx
Alternative Names: Indometacin/phosphatidylcholine; Indomethacin-PC; Indomethacin/phosphatidylcholine; Ketorolac/phosphatidylcholine; Meloxicam/phosphatidylcholine; Mesalazine (PL9100 5-ASA); Piroxicam-PC; Piroxicam/phosphatidylcholine; PL 4100; PL 4500; PL 9100 5-ASALatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator PLx Pharma
- Class
- Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase-cyclooxygenase inhibitors; Prostaglandin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Congenital heart defects; Gout; Inflammation; Pain; Ulcerative colitis
Most Recent Events
- 24 Feb 2023 Discontinued - Preclinical for Congenital heart defects in USA (IV) (PLx Pharma pipeline, February 2023)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Congenital-heart-disorders in USA (IV)
- 20 Oct 2017 Discontinued - Preclinical for Ulcerative colitis, Pain, Inflammation and Gout (PO), and Pain (IV) in USA (PLx Pharma pipeline, October 2017)